Former senior executive at Iqvia Inc
- Impact of current R&D funding environment on trial sponsor demand for CRO (contract research organisation) services and RFP (request for proposal) volumes
- Order book growth outlook, revenue conversion and potential for cancellation of contracted work
- Ability of CRO services providers to meet demand in light of labour shortages and cost pass-through dynamics
- Iqvia’s (NYSE: IQV) Q3 2022 performance and exposure to aforementioned market pressures
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.